UPDATED: Compugen Sees Q4 Revenue Triple; Plans New Product Launches | GenomeWeb

This story has been updated from a previous version.

NEW YORK, Feb 14 – Compugen said Wednesday its fourth-quarter revenues tripled to $3.3 million, compared with $1.1 million a year ago, while revenues for 2000 increased to $6.9 million from $3.2 million in 1999 due to collaborations with Pfizer and Human Genome Sciences as well as patent licensing revenue. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.